Showing 3331-3340 of 7329 results for "".
Take 5: Recent Developments in Systemic Therapy for Psoriasis
https://practicaldermatology.com/columns/recent-developments/take-5-recent-developments-in-systemic-therapy-for-psoriasis/22002/New data reveal noteworthy financial and clinical trends in the use of systemic agents.Cosmeceuticals: A Clinician's Guide to Science, Selection, Marketing, and Dispensing
https://practicaldermatology.com/topics/general-topics/cosmeceuticals-a-clinicians-guide-to-science-selection-marketing-and-dispensing/22007/Experienced physicians describe dispensing strategies that provide the greatest benefit to the patient and the practice.Take 5: Strategies to Fight Skin Cancer Trends
https://practicaldermatology.com/columns/take-5/take-5-strategies-to-fight-skin-cancer-trends/22035/On the 25th anniversary of the renowned ABCDE's of Melanoma, a contributor to the guidelines shares strategies to improve detection and bolster prevention efforts.Business Advisor: Mapping Out a Price/Benefit Value Strategy for Your Practice
https://practicaldermatology.com/topics/general-topics/business-advisor-mapping-out-a-pricebenefit-value-strategy-for-your-practice/22043/Using a Price/Benefit map is a good way for practices to set prices and plan to adapt to changing markets.A Busy Time in the Field
https://practicaldermatology.com/issues/januaryfebruary-2026/a-busy-time-in-the-field/54452/Remaking Ourselves: Aesthetic Medicine That Is Regenerative
https://practicaldermatology.com/issues/october-2025/remaking-ourselves-aesthetic-medicine-that-is-regenerative/39752/Mergers and Acquisitions in Derm and Aesthetics: Market Outlook
https://practicaldermatology.com/issues/september-2025/mergers-and-acquisitions-in-derm-and-aesthetics-market-outlook/37631/We took a deeper look into the dermatology and aesthetics mergers and acquisitions (M&A) market in a conversation with two of our team members, Drew Thomas and Jordan Frickle, who are closely involved in this sector. The following discussion brings together their perspectives on current trends,First Reported Case of Red Face Response to Tralokinumab in the United States
https://practicaldermatology.com/issues/september-2025/first-reported-case-of-red-face-response-to-tralokinumab-in-the-united-states/37639/The chronic nature of atopic dermatitis (AD), which currently affects approximately 10.8% of children and 7.3% of adults in the United States,1 makes long-term management challenging.The ESOP Model: An Alternative to PE for Dermatology Practices
https://practicaldermatology.com/issues/september-2025/the-esop-model-an-alternative-to-pe-for-dermatology-practices/37637/Not all practice models are as simple as private practice vs private equity. At Ada West Dermatology in Boise, Idaho, we’ve adopted a somewhat uncommon business model called an employee stock ownership plan (ESOP) and it’s worked very well for us.Journal Club: Dupilumab and Risk of Malignancy
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-dupilumab-and-risk-of-malignancy/32398/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, speaks with Matthew Zirwas, MD, about the Journal of Allergy and Clinical Immunology: In Practice article "Risk of malignancy associated with use of dupilumab versus other treatments in atopic dermatitis patients: A national database